



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/734573/2018  
EMA/H/C/004806

## Takhzyro (*lanadelumab*)

An overview of Takhzyro and why it is authorised in the EU

### What is Takhzyro and what is it used for?

Takhzyro is a medicine used to prevent attacks of hereditary angioedema in patients aged 12 years and over.

Patients with angioedema have rapid swelling under the skin in areas such as the face, throat, arms and legs. Attacks of hereditary angioedema can be life threatening when the swelling around the throat presses against the airway.

Takhzyro contains the active substance lanadelumab.

Hereditary angioedema is rare, and Takhzyro was designated an 'orphan medicine' (a medicine used in rare diseases) on 9 October 2015. Further information on the orphan designation can be found here: [ema.europa.eu/medicines/human/orphan-designations/eu3151551](http://ema.europa.eu/medicines/human/orphan-designations/eu3151551)

### How is Takhzyro used?

Takhzyro is given as an injection under the skin, preferably in the abdomen (belly), thighs or upper arms. The recommended starting dose of Takhzyro is 300 mg every 2 weeks. If the patient remains free of attacks with the two-weekly dose, the doctor can reduce the frequency to once every 4 weeks.

The doctor may decide that patients or their caregivers can inject the medicine themselves after they have been properly trained.

Takhzyro can only be obtained with a prescription and should be started under supervision of a doctor experienced in managing hereditary angioedema.

For more information about using Takhzyro, see the package leaflet or contact your doctor or pharmacist.



## **How does Takhzyro work?**

Patients with hereditary angioedema have high levels of a substance called 'bradykinin', which causes blood vessels to widen and leak fluid into the surrounding tissue leading to the swelling attacks seen in angioedema.

The active substance in Takhzyro, lanadelumab, works by attaching to and blocking an enzyme in the blood called 'kallikrein', which has several functions, including increasing levels of bradykinin. By blocking the actions of kallikrein, lanadelumab helps to prevent the swelling and related symptoms of angioedema.

## **What benefits of Takhzyro have been shown in studies?**

Takhzyro was found to be effective in reducing the number of angioedema attacks in a main study in 126 adults and children above 12 years of age with hereditary angioedema.

Patients experienced on average 0.3 attacks per month when given Takhzyro injections every 2 weeks and 0.5 attacks when given injections every 4 weeks. This compared with 2 attacks per month for patients on placebo (a dummy treatment).

## **What are the risks associated with Takhzyro?**

The most common side effects with Takhzyro (which may affect more than 1 patient in 10) are reactions at the site of injection including erythema (redness), bruising and pain.

For the full list of side effects and restrictions with Takhzyro, see the package leaflet.

## **Why is Takhzyro authorised in the EU?**

Takhzyro is effective in preventing angioedema attacks and the fact that it only needs to be given every 2 or 4 weeks was considered an advantage over existing treatments. Overall, the safety profile was considered acceptable.

The European Medicines Agency therefore decided that Takhzyro's benefits are greater than its risks and it can be authorised for use in the EU.

## **What measures are being taken to ensure the safe and effective use of Takhzyro?**

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Takhzyro have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Takhzyro are continuously monitored. Side effects reported with Takhzyro are carefully evaluated and any necessary action taken to protect patients.

## **Other information about Takhzyro**

Takhzyro received a marketing authorisation valid throughout the EU on 22 November 2018.

Further information on Takhzyro can be found on the Agency's website:

[ema.europa.eu/medicines/human/EPAR/Takhzyro](http://ema.europa.eu/medicines/human/EPAR/Takhzyro).

This overview was last updated in 11-2018.